secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001558370-24-011201
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q2 net loss narrows to $11.0M; cash runway extended into 2028 via $26.5M royalty sale
--------------------------------------------------------------------------------

- Revenue $2.8M (+47% YoY) driven by higher Lilly royalties; net loss $11.0M vs $29.6M.
- Cash, equivalents and securities $149.9M; July 2024 received $26.5M upfront from OLUMIANT royalty sale.
- Phase 2a trial of ATI-2138 in atopic dermatitis initiated; enrollment expected in coming weeks.
- Seeking global partner for lepzacitinib (ATI-1777) after positive Phase 2b top-line results.
- R&D expense fell 65% to $8.8M due to completion of several clinical trials and headcount reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024011201/0001558370-24-011201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024011201/acrs-20240807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-011201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer